TIMP1 and systemic sclerosis: However, in SSc patients, MMP-3 activity is suppressed due to elevated levels of anti-MMP-3 autoantibodies and increased expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), thereby reducing α2AP degradation [115,116].